By Jennifer Schiro, nurse practitioner and Whole30 Certified Coach This information is for educational purposes only. It is not intended nor implied to be a substitute for professional medical advice. Always consult healthcare provider to determine the appropriateness of the information for your own situation. As a nurse practitioner, functional […]
I understand the concept of what they’re trying to say, but I feel awkward likening a lackluster cauliflower pizza to dry humping. We’re going to be practicing abstinence for those 30 days. In short, keep your pants on and don’t try to make pancakes. It’s too sexy. It might tempt you to take your pants off eventually and go full-pancake. I’m going to stop talking about taking my pants off now. Perfect.
Overall, my biggest Whole30 lesson is that mindful eating is possible. I don't have that urge to eat everything in sight, but I also know I don't need to deprive myself or worry about food 24/7. There's a happy medium where I get to decide what I really crave, weigh whether it's worth the bloat or restless sleep I might experience after eating it, and then say yes or no. I've caught myself thinking like this more, and so the ultimate goal of Whole30 has worked: I've changed my relationship with food—for the better.
As CrossFit gets bigger and bigger, Glassman is no longer the underdog. Well-known employees and boxes have been tossed out after clashing with Glassman or voicing disagreements with the CrossFit approach to fitness or nutrition--or, in particular, criticizing other CrossFitters close to Glassman. In 2009, Robb Wolf, one of the first affiliates, was exiled. "You have to kowtow and not let your star shine too brightly," Wolf says. "He's always had this tendency toward incredible kindness, but he also has this rattlesnake intensity and cruelty."
The WHO trial (so named because the international team of principal investigators contained World Health Organization members) tested the potential of clofibrate, a “pre-statin” cholesterol-lowering agent, to reduce heart attack morbidity and mortality. The investigators ultimately concluded that clofibrate "cannot be recommended as a lipid-lowering drug for community-wide primary prevention of ischaemic heart disease.” Nevertheless, clofibrate remained in use until 2002, when it was pulled for increasing cancer rates. In their review of studies such as the WHO trial, Uffe Ravnskov and David Diamond observe, “Despite the largely disappointing findings from 50 years of cholesterol lower[ing] trials, the indictment and conviction of cholesterol as the causal agent in CVD [cardiovascular disease] has stood the test of time. … [Yet] the grand effort to reduce cholesterol as a strategy to improve health has failed.”